Browse the corpus

REFERENCES Burmester GR, Panaccione R, Gordon KB, et al, "Adalimumab: Long-Term Safety in 23 458 Patients From Global Clinical Trials in Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis and Crohn's Disease," Ann Rheum Dis , 2012. [PubMed 22562972 ] Dommasch E and Gelfand JM, “Is There Truly a Risk of Lymphoma From Biologic Therapies?” Dermatol Ther , 2009, 22 (5):418-30. Gordon KB, Langley RG, Leonardi C, et al, “Clinical Response to Adalimumab Treatment in Patients With Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and Open-Label Extension Study,” J Am Acad Dermatol , 2006, 55(4):598-606. [PubMed 17010738 ] Keystone EC, Kavanaugh AF, Sharp JYT, et al, “Radiographic, Clinical, and Functional Outcomes of Treatment With Adalimumab (A Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial,” Arthritis Rheum , 2004, 50(5):1400-11. [PubMed 15146409 ] Lichtenstein GR, Hanauer SB, and Sandborn WJ, “Management of Crohn's Disease in Adults,” Am J Gastroenterol , 2009, 104(2):465-83. [PubMed 19174807 ] Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, “Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,” JAMA , 2012, 308(9): 898-908. [PubMed 22948700 ] Parakkal D, Sifuentes H, Semer R, et al, “Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-α Inhibitor Therapy: Expanding the Groups at Risk,” Eur J Gastroenterol Hepatol , 2011, 23(12):1150-6. [PubMed 21941193 ] Sandborn WJ, Rutgeerts P, Enns R, et al, "Adalimumab Induction Therapy for Crohn Disease Previously Treated With Infliximab: A Randomized Trial.," Ann Intern Med , 2007, 146(12):829-38. [PubMed 17470824 ] Singh JA, Furst DE, Bharat A, et al, “2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,” Arthritis Care Res (Hoboken) , 2012, 64(5):625-39. [PubMed 22473917 ] van der Heijde D, Kivitz A, Schiff MH, et al, “Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,” Arthritis Rheum , 2006, 54(7):2136-46. [PubMed 16802350 ]

Singh JA, Furst DE, Bharat A, et al, “2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,” Arthritis Care Res (Hoboken) , 2012, 64(5):625-39. [PubMed 22473917 ] van der Heijde D, Kivitz A, Schiff MH, et al, “Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,” Arthritis Rheum , 2006, 54(7):2136-46. [PubMed 16802350 ] Topic 8583 Version 47.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]